Pharma Stocks
-
Banking giant massively resets Jazz Pharma stock price target
Changes in Wall Street price targets usually arrive in small increments. A few dollars up, a few dollars down, and…
Read More » -
Will Real-World SUBLOCADE Adherence Data Reshape Indivior Pharmaceuticals’ (INDV) Long-Acting OUD Treatment Narrative
In May 2026, Indivior Pharmaceuticals reported two real-world evidence studies showing that adherence to its monthly injectable buprenorphine, SUBLOCADE, was…
Read More » -
Why The Cipher Pharmaceuticals (TSX:CPH) Story Is Shifting As Analysts Lift Valuation Targets
Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge. Cipher Pharmaceuticals is…
Read More » -
Here’s Why We Think AFT Pharmaceuticals (NZSE:AFT) Is Well Worth Watching
Investors are often guided by the idea of discovering ‘the next big thing’, even if that means buying ‘story stocks’…
Read More » -
Scilex Holding Company (“Scilex”) Announces Its Board of Directors Approved a Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities with a Record Date of June 1, 2026
PALO ALTO, Calif., May 22, 2026 (GLOBE NEWSWIRE) — Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative…
Read More » -
Morgan Stanley Raises its Price Target on Jazz Pharmaceuticals (JAZZ)
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is one of the 10 Best European Growth Stocks to Buy. On May 7, 2026, Morgan…
Read More » -
Infosys, TCS to LTIMindtree: IT stocks look cheap after up to 33% YTD fall, but upside may remain limited, say analysts
Indian IT stocks have remained under intense selling pressure over the past year amid global macroeconomic headwinds, muted earnings growth,…
Read More » -
Analysts Have Made A Financial Statement On Mankind Pharma Limited’s (NSE:MANKIND) Yearly Report
It’s been a good week for Mankind Pharma Limited (NSE:MANKIND) shareholders, because the company has just released its latest annual…
Read More » -
Do HELIOS Data Shift Amylyx (AMLX) From ALS Setback To Broader Rare-Disease Strategy Reboot?
Amylyx Pharmaceuticals recently reported that 24- and 48-week results from its Phase 2 open-label HELIOS trial of AMX0035 in adults…
Read More » -
CU6) Rises 9% as Traders Rotate Into Biotech Stocks
Shares of Clarity Pharmaceuticals Ltd. (ASX: CU6) climbed 9.33% on 21 May 2026 to A$2.76 per share, registering a notable…
Read More »